Quick Answer
Phathom Pharmaceuticals, Inc. reported Diluted EPS of $3.03 per share (loss) for fiscal year 2025.
Phathom Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.03 | +42.7% |
| 2024 | -$5.29 | -34.6% |
| 2023 | -$3.93 | +22.2% |
| 2022 | -$5.05 | -29.8% |
| 2021 | -$3.89 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.41 | +68.9% | +61.0% |
| June 30, 2025 | -$1.05 | +32.7% | +19.8% |
| March 31, 2025 | -$1.31 | +7.7% | +0.8% |
| September 30, 2024 | -$1.32 | -73.7% | +15.4% |
| June 30, 2024 | -$1.56 | -85.7% | -9.9% |
| March 31, 2024 | -$1.42 | -59.6% | -86.8% |
| September 30, 2023 | -$0.76 | +42.4% | +9.5% |
| June 30, 2023 | -$0.84 | +36.8% | +5.6% |
- Phathom Pharmaceuticals, Inc. showed an increase of +42.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Phathom Pharmaceuticals, Inc.’s diluted eps has grown by 22.1% (from $3.89 per share (loss) to $3.03 per share (loss)).
- The most recent figure is from Phathom Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: